Premium
A PRELIMINARY REPORT ON THE USE OF THE DEPOT SULPHONE PREPARATION ACEDAPSONE (“HANSOLAR”) IN THE CONTROL OF LEPROSY
Author(s) -
Boughton C. R.,
Scott G. C.,
Russell D. A.,
Vincin D. R.
Publication year - 1971
Publication title -
medical journal of australia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 131
eISSN - 1326-5377
pISSN - 0025-729X
DOI - 10.5694/j.1326-5377.1971.tb92385.x
Subject(s) - leprosy , depot , medicine , geography , dermatology , archaeology
A preliminary report is presented of the results of two years' treatment of a group of leprosy patients with a depot sulphone preparation. The drug is a diacetyl derivative of diaminodiphenyl sulphone (acedapsone, “Hansolar”, Parke Davis), which is administered by intramuscular injection every 75 days. The clinical and bacteriological response of 327 patients has been very satisfactory, and this form of treatment has been accepted by the population. Administration of the drug has resulted in reduction of infectivity of patients with dimorphous and lepromatous leprosy, as measured by the morphological and bacterial indices. There has been no indication to date of the development of resistance by Mycobacterium lepræ to acedapsone. This drug offers considerable advantages over orally administered medication in the control of leprosy, particularly in underdeveloped areas where leprosy is endemic.